Table 4 Comparison of the microbiological characteristics with monomicrobial SA-BSI and polymicrobial SA-BSI
Total (n = 349) | Mono-SA-BSI (n = 295) | Poly-SA-BSI (n = 54) | p-value | |
|---|---|---|---|---|
Source of BSIs | ||||
Pneumonia | 93 (26.6%) | 69 (23.4%) | 24 (44.4%) | 0.00 |
Hospital-acquired pneumonia | 69 (74.2%) | 47 (68.1%) | 22 (91.7%) | 0.02 |
Community-acquired pneumonia | 24 (25.8%) | 22 (31.9%) | 2 (8.3%) | |
Skin and Soft tissue infection | 86 (24.6%) | 69 (23.4%) | 16 (29.6%) | 0.33 |
Central venous catheter | 65 (18.6%) | 61 (20.7%) | 4 (7.4%) | 0.04 |
Intra-abdominal | 42 (12%) | 34 (11.5%) | 8 (14.8%) | 0.50 |
Primary BSI | 28 (7.7%) | 27 (9.2%) | 1 (1.9%) | 0.10 |
Bone and joint | 14 (4.0%) | 14 (4.7%) | 0 (0%) | 0.14 |
Endocarditis | 11 (3.2%) | 11 (3.7%) | 0 (0%) | 0.23 |
Urinary tract infection | 9 (2.6%) | 8 (2.7%) | 1 (1.9%) | 0.58 |
Others* | 2 (0.6%) | 2 (0.7%) | 0 (0%) | 0.71 |
MRSA | 236 (67.6%) | 192 (65.1%) | 44 (81.5%) | 0.02 |
Delayed antibiotic therapy | 29 (8.3%) | 24 (8.1%) | 5 (9.3%) | 0.78 |
Antibiotic resistancea | ||||
Cefoxitin (115 vs 25)b | 114 (81.4%) | 89 (77.4%) | 25 (100%) | 0.01 |
Ciprofloxacin (237 vs 42)b | 132 (47.3%) | 96 (40.5%) | 36 (85.5%) | 0.00 |
Clindamycin (295 vs 54)b | 127 (36.4%) | 110 (37.3%) | 17 (31.5%) | 0.42 |
Erythromycin (295 vs 54)b | 203 (58.2%) | 167 (56.6%) | 36 (66.7%) | 0.17 |
Gentamicin (295 vs 54)b | 58 (16.6%) | 50 (16.9%) | 8 (14.8%) | 0.71 |
Levofloxacin (261 vs 49)b | 161 (51.9%) | 118 (45.2%) | 43 (87.8%) | 0.00 |
Linezolid (293 vs 54)b | 46 (13.3%) | 37 (12.6%) | 9 (16.7%) | 0.42 |
Moxifloxacin (287 vs 51)b | 158 (46.7%) | 117 (40.8%) | 41 (80.4%) | 0.00 |
Nitrofurantoin (255 vs 50)b | 1 (0.3%) | 1 (0.4%) | 0 (0%) | 1 |
Oxacillin (295 vs 54)b | 236 (67.6%) | 192 (65.1%) | 44 (81.5%) | 0.02 |
Penicillin (295 vs 54)b | 333 (95.4%) | 279 (94.6%) | 54 (100%) | 0.08 |
Quinupristin/Dalfopristin (295 vs 54)b | 44 (12.6%) | 36 (12.2%) | 8 (14.8%) | 0.60 |
Rifampin (242 vs 43)b | 9 (3.2%) | 8 (3.3%) | 1 (2.3%) | 1 |
Tetracycline (230 vs 50)b | 148 (52.9%) | 112 (48.7%) | 36 (72%) | 0.00 |
Vancomycin (278 vs 49)b | 48 (14.3%) | 39 (13.6%) | 9 (18.4%) | 0.38 |